REGN1033

Phase 2Small molecule

Regeneron

REGN1033 is one of 90 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

ObesityActive, not recruiting

SarcopeniaActive, not recruiting

Type 2 Diabetes MellitusPhase 1

Active, not recruiting

ObesityPhase 1

Active, not recruiting

SarcopeniaPhase 2

Active, not recruiting

Competition

Competitive Landscape

676 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

Byetta

AstraZeneca

Preclinical

20 2

Insulin 320

Novo Nordisk

Preclinical

43 3

REGN1033

Regeneron

Phase 2

6 4

Adenocard

Astellas

Preclinical

1 5

NOVOLIN R

Novo Nordisk

Preclinical

1 6

Dostinex

Golytely

Cipro

Myrbetriq

Lantus

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

ESS2 trials

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)

Completed· Regeneron logo

Regeneron·Phase 1·NCT01720576·60 enrolled

Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)

Completed· Regeneron logo

Regeneron·Phase 1·NCT01910220·125 enrolled

Concentration1 trial

Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects

Completed· Regeneron logo

Regeneron·Phase 1·NCT02741739·28 enrolled

Sarcopenia1 trial

Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia

Completed· Regeneron logo

Regeneron·Phase 2·NCT01963598·253 enrolled

Single Ascending Dose1 trial

A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)

Completed· Regeneron logo

Regeneron·Phase 1·NCT01507402·76 enrolled

Postmenopausal Women1 trial

Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men

Completed· Regeneron logo

Regeneron·Phase 1·NCT02943239·82 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for REGN1033. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REGN1033 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REGN1033. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Regeneron

REGN1033

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

ESS2 trials

Concentration1 trial

Sarcopenia1 trial

Single Ascending Dose1 trial

Postmenopausal Women1 trial

References

Drug Info

Quick Facts

Related News